Last update May 11, 2019
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
موكسونيدين is Moxonidine in Arabic.Is written in other languages:
موكسونيدين belongs to this group or family:
Main tradenames from several countries containing موكسونيدين in its composition:
|VD||1.8 ± 0.4||l/Kg|
|Tmax||0.5 - 3||hours|
|T½||2 - 3||hours|
|M/P ratio||1 - 2||-|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A centrally-acting antihypertensive and antiadrenergic agent structurally related to clonidine.
Indicated in the treatment of hypertension.
Oral administration once a day.
Its pharmacokinetic data - low plasma protein binding and low molecular weight (Kirsten 1998) - may possibly explain the excretion in breastmilk observed, whose amount could affect the infant (Schaefer 2007 p685, Schaefer 1998).
Moxonidine does not cause alterations in the secretion of prolactin (Bamberger 1995).
Until there is more published data on this drug in relation to breastfeeding (Schaefer 2007 p685), safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.